Diagnosis. Monoclonal T-cell lymphoproliferative disorder, potentially induced by imatinib. Management. Imatinib was stopped, after which the tumor lesions spontaneously regressed and, eventually ...

Calquence is under clinical development by AstraZeneca and currently in Phase II for Primary Mediastinal B-Cell Lymphoma.